USFDA concludes PAI, GMP inspection at Gland Pharma’s Pashamylaram facility

28 Jun 2023 Evaluate

United States Food and Drug Administration (USFDA) has concluded Pre-Approval Inspection (PAI) for Seven Products and Good Manufacturing Practice (GMP) Inspection at the Gland Pharma’s Pashamylaram facility at Hyderabad between June 15, 2023 and June 27, 2023.

The inspection was concluded with (1) 483 observation. This observation is procedural in nature and the corrective and preventive actions for this observation will be submitted to the USFDA within the stipulated period. The observation issued is neither a repeated observation nor related to data integrity.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1888.65 7.75 (0.41%)
24-May-2024 15:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1486.55
Dr. Reddys Lab 5860.25
Cipla 1482.55
Zydus Lifesciences 1072.35
Lupin 1613.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.